Global leader in recombinant protein & life sciences tools, serving 8000+ customers over 70 countries.Listed in 2021 at $B market cap. With the new round of $300MM IPO financing, we are eager to deploy capital & partner with world-class innovators, explore new investment & tech transfer opportunities.Manage Acro’s global corporate development, tech transfer, investment, M&A, licensing activities (BD&L); oversee Acro innovation hub and innovative endeavors, like the Aneuro group.

Invest in early to growth stage healthcare & deep tech ventures

Incubated and spinoff Neurostimulation company from university, constructed team, clinical approval expected in 2024 to intervene mild cognitive impairment, depression, unconsciousness

Committee member of ONG-FECFC， Asia Peace Charity Foundation; Promote cultural exchange between France and Asia

Accelerate clinical trial recruitment and drug discovery

Incubate biotech startups from Harvard, MIT, and the greater Boston area

Focus on the next generation on problems worth solving.

Created novel nanoparticle formulation models for controlled drug deliveryConstructed machine learning pipeline to analyze drug properties and predict molecule candidates

SecretPigeon - B2C SASS for personal security issues. Top 8 global finalist at Technovation ChallengeB2B2C Utilities SASS 01890 connects local residents with community resources; collaborated and acquired by local nonprofit organization, featured in various news and media channels (Boston Globe, etc.).

Analyzed early-stage tech startups and performed due diligenceFocused on the fields of artificial intelligence, virtual reality, hardware, and biotechnology

-Optimized and helped develop cell lineage conversion protocol (fibroblasts to neurons) through experimental validation and bioinformatics analysis; potential future applications in cell therapy and personalized medicine-Conducted data analysis for a discovered novel disease-monitoring imaging technique for amyotrophic lateral sclerosis. -Co-authored work published on Nature Communications:Tian F, Yang W, Mordes DA, Wang JY, Salameh JS, Mok J, Chew J, Sharma A, Leno-Duran E, Suzuki-Uematsu S, Suzuki N, Han SS, Lu FK, Ji M, Zhang R, Liu Y, Strominger J, Shneider NA, Petrucelli L, Xie XS, Eggan K. Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nat Commun. 2016;7:13283http://www.nature.com/articles/ncomms13283